$0.75
6.38%
Nasdaq, Fri, Jan 02 2026
ISIN
US1850631045
Symbol
CLSD

Clearside Biomedical, Inc. Target price 2026 - Analyst rating & recommendation

Clearside Biomedical, Inc. Classifications & Recommendation:

Hold
73%
Sell
27%

Clearside Biomedical, Inc. Price Target

Target Price $76.50
Price $0.75
Potential
Number of Estimates 7
7 Analysts have issued a price target Clearside Biomedical, Inc. 2027 . The average Clearside Biomedical, Inc. target price is $76.50. This is higher than the current stock price. The highest price target is
$94.50 12,500.00%
register free of charge
, the lowest is
$30.30 3,940.00%
register free of charge
.
A rating was issued by 11 analysts: 0 Analysts recommend Clearside Biomedical, Inc. to buy, 8 to hold and 3 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Clearside Biomedical, Inc. stock has an average upside potential 2027 of . Most analysts recommend the Clearside Biomedical, Inc. stock at Hold.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 1.66 3.30
79.83% 98.67%
EBITDA Margin -1,726.51% -535.33%
473.41% 68.99%
Net Margin -2,069.28% -521.65%
424.17% 74.79%

9 Analysts have issued a sales forecast Clearside Biomedical, Inc. 2025 . The average Clearside Biomedical, Inc. sales estimate is

$3.3m
Unlock
. This is
20.91% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$3.7m 11.87%
Unlock
, the lowest is
$2.7m 34.20%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $1.7m 79.83%
2025
$3.3m 98.67%
Unlock
2026
$10.3m 213.77%
Unlock
2027
$15.3m 47.46%
Unlock
2028
$25.1m 64.47%
Unlock
2029
$107m 325.41%
Unlock
2030
$185m 73.66%
Unlock
2031
$196m 5.73%
Unlock
2032
$290m 48.14%
Unlock

3 Analysts have issued an Clearside Biomedical, Inc. EBITDA forecast 2025. The average Clearside Biomedical, Inc. EBITDA estimate is

$-17.7m
Unlock
. This is
18.00% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-18.2m 15.59%
Unlock
, the lowest is
$-17.0m 21.21%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-28.7m 15.66%
2025
$-17.7m 38.40%
Unlock
2026
$-7.4m 58.05%
Unlock
2027
$-11.0m 48.59%
Unlock

EBITDA Margin

2024 -1,726.51% 473.41%
2025
-535.33% 68.99%
Unlock
2026
-71.57% 86.63%
Unlock
2027
-72.12% 0.77%
Unlock

9 Clearside Biomedical, Inc. Analysts have issued a net profit forecast 2025. The average Clearside Biomedical, Inc. net profit estimate is

$-17.2m
Unlock
. This is
37.93% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-15.7m 43.52%
Unlock
, the lowest is
$-18.5m 33.42%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-34.4m 5.72%
2025
$-17.2m 49.93%
Unlock
2026
$-7.2m 58.14%
Unlock
2027
$-13.6m 88.89%
Unlock
2028
$-4.0m 70.59%
Unlock
2029
$68.8m 1,820.50%
Unlock
2030
$92.0m 33.71%
Unlock
2031
$114m 23.48%
Unlock
2032
$174m 53.52%
Unlock

Net Margin

2024 -2,069.28% 424.17%
2025
-521.65% 74.79%
Unlock
2026
-69.60% 86.66%
Unlock
2027
-89.15% 28.09%
Unlock
2028
-15.94% 82.12%
Unlock
2029
64.46% 504.39%
Unlock
2030
49.63% 23.01%
Unlock
2031
57.96% 16.78%
Unlock
2032
60.07% 3.64%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -6.98 -3.29
11.42% 52.87%
P/E negative
EV/Sales negative

9 Analysts have issued a Clearside Biomedical, Inc. forecast for earnings per share. The average Clearside Biomedical, Inc. EPS is

$-3.29
Unlock
. This is
38.27% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.99 43.90%
Unlock
, the lowest is
$-3.53 33.77%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-6.98 11.42%
2025
$-3.29 52.87%
Unlock
2026
$-1.38 58.05%
Unlock
2027
$-2.60 88.41%
Unlock
2028
$-0.77 70.38%
Unlock
2029
$13.16 1,809.09%
Unlock
2030
$17.60 33.74%
Unlock
2031
$21.73 23.47%
Unlock
2032
$33.35 53.47%
Unlock

P/E ratio

Current -0.14 93.78%
2025
-0.23 63.47%
Unlock
2026
-0.54 134.78%
Unlock
2027
-0.29 46.30%
Unlock
2028
-0.98 237.93%
Unlock
2029
0.06 106.12%
Unlock
2030
0.04 33.33%
Unlock
2031
0.03 25.00%
Unlock
2032
0.02 33.33%
Unlock

Based on analysts' sales estimates for 2025, the Clearside Biomedical, Inc. stock is valued at an EV/Sales of

-1.59
Unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -1.26 120.03%
2025
-1.59 26.34%
Unlock
2026
-0.51 68.13%
Unlock
2027
-0.34 32.17%
Unlock
2028
-0.21 39.20%
Unlock
2029
-0.05 76.48%
Unlock
2030
-0.03 42.48%
Unlock
2031
-0.03 5.30%
Unlock
2032
-0.02 32.46%
Unlock

P/S ratio

Current 0.99 89.40%
2025
1.25 26.29%
Unlock
2026
0.40 68.13%
Unlock
2027
0.27 32.17%
Unlock
2028
0.16 39.19%
Unlock
2029
0.04 76.49%
Unlock
2030
0.02 42.38%
Unlock
2031
0.02 5.38%
Unlock
2032
0.01 32.70%
Unlock

Current Clearside Biomedical, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Needham
Locked
Locked
Locked Nov 18 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 18 2025
Chardan Capital
Locked
Locked
Locked Jul 18 2025
Needham
Locked
Locked
Locked Jul 17 2025
HC Wainwright & Co.
Locked
Locked
Locked May 23 2025
JMP Securities
Locked
Locked
Locked May 16 2025
Needham
Locked
Locked
Locked May 15 2025
Analyst Rating Date
Locked
Needham:
Locked
Locked
Nov 18 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 18 2025
Locked
Chardan Capital:
Locked
Locked
Jul 18 2025
Locked
Needham:
Locked
Locked
Jul 17 2025
Locked
HC Wainwright & Co.:
Locked
Locked
May 23 2025
Locked
JMP Securities:
Locked
Locked
May 16 2025
Locked
Needham:
Locked
Locked
May 15 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today